These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 24429127

  • 21. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
    Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
    [Abstract] [Full Text] [Related]

  • 22. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ, Neffen H.
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D.
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [Abstract] [Full Text] [Related]

  • 25. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG, Capuano A, Cazzola M.
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [Abstract] [Full Text] [Related]

  • 26. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
    Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S.
    Chest; 2014 Dec; 146(6):1521-1530. PubMed ID: 25058845
    [Abstract] [Full Text] [Related]

  • 27. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF.
    Lancet; 2015 Mar 07; 385(9971):857-66. PubMed ID: 25684586
    [Abstract] [Full Text] [Related]

  • 28. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, Vestbo J, SUMMIT investigators.
    Respir Med; 2017 Oct 07; 131():27-34. PubMed ID: 28947039
    [Abstract] [Full Text] [Related]

  • 29. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.
    Martinez FJ, Vestbo J, Anderson JA, Brook RD, Celli BR, Cowans NJ, Crim C, Dransfield M, Kilbride S, Yates J, Newby DE, Niewoehner D, Calverley PM, SUMMIT Investigators.
    Am J Respir Crit Care Med; 2017 Apr 01; 195(7):881-888. PubMed ID: 27767328
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Apr 01; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 31. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D, Salford Lung Study Investigators.
    Lancet; 2017 Nov 18; 390(10109):2247-2255. PubMed ID: 28903864
    [Abstract] [Full Text] [Related]

  • 32. Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial.
    Maltais F, Schenkenberger I, Wielders PLML, Ortiz de Saracho J, Chinsky K, Watkins M, Millar V, Crim C.
    Ther Adv Respir Dis; 2020 Nov 18; 14():1753466620965145. PubMed ID: 33081606
    [No Abstract] [Full Text] [Related]

  • 33. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul 18; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan 18; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 35. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 18; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 36. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
    Kew KM, Seniukovich A.
    Cochrane Database Syst Rev; 2014 Mar 10; 2014(3):CD010115. PubMed ID: 24615270
    [Abstract] [Full Text] [Related]

  • 37. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.
    Caramori G, Chung KF, Adcock IM.
    Int J Chron Obstruct Pulmon Dis; 2014 Mar 10; 9():249-56. PubMed ID: 24596460
    [Abstract] [Full Text] [Related]

  • 38. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.
    Respir Med; 2019 Feb 10; 147():58-65. PubMed ID: 30704700
    [Abstract] [Full Text] [Related]

  • 39. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED, O'Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A.
    Thorax; 2014 Apr 10; 69(4):312-9. PubMed ID: 24253831
    [Abstract] [Full Text] [Related]

  • 40. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M, Nardin M, Santini G, Mores N, Radaeli A, Montuschi P.
    Ther Adv Respir Dis; 2018 Apr 10; 12():1753466618760779. PubMed ID: 29537340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.